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Cardiovascular mortality is increased in transplant recipients.
However, studies including non-fatal events are critical to
assess the burden of disease and to identify novel risk
factors. We described the incidence of fatal and non-fatal
events, and explored associations and interactions among
traditional and transplant-specific risk factors and
cardiovascular events (CVE) in a cohort of 922 patients
transplanted between 1993 and 1998. One hundred and
seventy-six patients experienced 201 CVE (111 cardiac, 48
cerebrovascular, 42 peripheral-vascular). Most CVE were non-
fatal. Factors associated with cardiac events were (adjusted
hazard ratios) tobacco (3.53; Po0.001), obesity (2.92;
Po0.001), diabetes (2.63; Po0.001), multiple rejections (2.19;
P¼ 0.008), prior CVE (2.0; P¼ 0.004), dialysis 41 year (1.91;
P¼ 0.007), and overweight status (1.68; P¼ 0.04); with
cerebrovascular events: diabetes and peritoneal dialysis
(11.95; Po0.001), age 445 (6.77; Po0.001), diabetes (4.87;
Po0.001), prior CVE (3.73; Po0.001), creatinine 4141 lmol/l
(3.16; P¼ 0.001), peritoneal dialysis (3.06; P¼ 0.027), and
obesity (0.32; P¼ 0.046); with peripheral-vascular events:
diabetes (8.48; Po0.001), tobacco and cytomegalovirus (3.88;
Po0.001), age 445 (2.31; P¼ 0.019), and prior CVE (2.25;
P¼ 0.016); with mortality: tobacco and deceased-donor
(3.52; Po0.001), age 445 (1.81; P¼ 0.002), diabetes (1.76;
P¼ 0.002), pulse pressure (1.64; P¼ 0.029), prior CVE (1.52;
P¼ 0.04), and dialysis 41 year (1.47; P¼ 0.04). The majority
of CVE post-transplant were non-fatal. Previous CVE was
strongly associated with CVE post-transplant. Interactions
among transplant-specific and traditional risks impacted
significantly the incidence of CVE. Modifiable factors such as
duration of dialysis, deceased-donor transplantation, and
acute rejection should be viewed as cardiovascular risks.
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Patients with chronic kidney disease are at increased risk for
premature cardiovascular disease and mortality associated
with cardiovascular events (CVE).1 Similar to the general
population, the majority of deaths following renal transplant-
ation are due to CVE. Analysis of traditional cardiovascular
risks failed to explain the increased incidence of CVE
experienced by the transplant population;2 thus, it is
speculated that a unique set of factors are responsible for
this phenomenon. Furthermore, detailed analyses of interact-
ions between traditional and transplant-specific factors have
not been explored.
Mortality owing to cardiovascular disease has decreased
steadily in the United States over the last decade, despite a
simultaneous increase in its incidence,3 a phenomenon
explained by improvements in acute care of individuals
experiencing CVE. Such changes in the profiles of outcomes
may result in underestimation of the burden of cardio-
vascular disease, if mortality is the sole end point studied.
National transplant registries, although containing detailed
demographic variables and survival data, are less reliable
sources for outcomes such as non-fatal CVE. In addition,
owing to variable insurance coverage and restricted Medicare
entitlement following transplantation, the United States
Renal Data System (USRDS) has limited long-term trans-
plant follow-up data. Finally, publications using large
databases have failed to adjust their models for important
pre-existing conditions, such as history of CVE or tobacco
smoking before transplantation.4,5
To address these pitfalls, we conducted a single-center
cohort study utilizing a closely monitored renal transplant
population where cardiovascular outcomes data have been
collected in a prospective fashion over a period longer than a
decade. The main goals of this study were (1) to describe the
incidences of fatal and non-fatal CVE, further categorized as
cardiac, cerebrovascular, and peripheral vascular events; and
(2) to describe interactions among traditional and trans-
plant-specific cardiovascular risk factors in the incidence of
CVE post-transplantation.
RESULTS
Between 1 January 1991 and 31 December 1998, 950
transplants were performed on 922 patients (26 patients
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received two and one patient three transplants during the
observation period). Mean age at transplantation was
44.270.4 (s.e.m.) years, mean systolic and diastolic blood
pressure were 136.670.64 and 82.770.39 mm Hg respec-
tively, and the mean cholesterol level at transplantation was
5.370.05 mmol/l (204.871.8 mg/dl). A mean of 23.370.98
months was described for those patients on dialysis before
transplantation. Table 1 shows additional demographics data.
All patients were accounted for the first year and 17 (1.8% of
the cohort) were lost to follow-up at the 5-year time point. A
total of 6947 patient-years of follow-up were accrued during
the study period.
One hundred and seventy-six patients (19%) experienced
201 CVE (4.42 events per 100 patient-years). One
hundred and eleven patients had a cardiac event
(65 myocardial infarcts, 18 coronary artery bypasses, 16
angioplasties, and 12 new-onset angina pectoris), 48 a
cerebrovascular event (39 cerebrovascular accidents, six
transient ischemic attacks, and three carotid endarterecto-
mies), and 42 a peripheral-vascular event (22 amputations,
18 revascularizations, and two new-onset claudications). One
hundred and ninety-two patients (21%) expired, 56 (29%)
deaths were owing to CVE (39 cardiac deaths and 17
cerebrovascular deaths; 1.23 fatal CVE per 100 patient-years).
Seventy-one percent of CVE did not result in death (35% of
cardiac events, 35% of cerebrovascular events, and none of
peripheral-vascular events were recorded within 30 days of
the recorded date of death). Of the cardiac deaths 12
occurred within 30 days of a myocardial infarct (seven
deaths) or a revascularization procedure (five deaths). The
remaining cardiac deaths, were determined by review of
death certificates.
Table 2 shows the results of the univariate analysis for the
primary outcome: transplantation after 1995, age older than
45, male gender, deceased-donor transplant, delayed graft
function (DGF), history of diabetes, tobacco smoking, and
CVE before transplantation were associated with increased
risk for cardiac events after transplantation. Obese indivi-
duals, those within the highest tertile of pulse pressure at
transplantation, and those on dialysis longer than 1 year also
experienced more cardiac events. Hypercholesterolemia and
hypertension because of their biological significance, were
entered in the multivariable models. In the complete model
(Table 3), prior CVE, diabetes, tobacco smoking, obesity,
multiple rejections, and dialysis 41 year were significant
independent variables associated with cardiac events follow-
ing renal transplantation. The ‘best-fit’ reduced model
(Table 4) identified tobacco smoking, obesity, pre-existing
diabetes, multiple rejection episodes, prior CVE, overweight
status, and dialysis 41 year as significant risk factors. Age
445 and a single rejection episode were not independently
associated with cardiac events but contributed to the best-fit
of the model. Body mass index was also significant when
entered in the model as a continuous variable (adjusted
hazard ratio 1.08; 95% confidence interval (CI) 1.04–1.13;
Po0.001).
Explanatory variables associated with cerebrovascular
events in the univariate analyses included age 445
(Po0.001), diabetes (Po0.001), prior CVE (Po0.001),
peritoneal dialysis (P¼ 0.002), deceased-donor transplant
(P¼ 0.005), hypercholesterolemia (P¼ 0.02), cytomegalo-
virus (CMV) infection (P¼ 0.03), and elevated pulse pressure
at 3 months (P¼ 0.03). An elevated 3-month creatinine level
(P¼ 0.08), re-transplantation status (P¼ 0.11), dialysis 41
year (P¼ 0.13), transplantation after 1994 (P¼ 0.12), and
obesity at transplantation (P¼ 0.19) were also included in
the models. An interaction between peritoneal dialysis and
diabetes mellitus was detected. Therefore, an interaction term
diabetes*peritoneal dialysis was entered in the multivariable
Table 1 | Demographics of the study cohort
Variable Categories N (%)
Year of
transplantation
1991–1994 444 (48)
1995–1998 478 (52)
Age (at
transplantation)
18–45 years 495 (54)
445 years 427 (46)
Gender Female/male 402 (44)/520 (56)
Ethnicity Caucasian 786 (85)
Black 40 (4.3%)
Hispanic 37 (4%)
Asians or other 59 (6.4%)
Transplant number 1/41 791 (86%)/131 (14%)
Type of donor Living/deceased 243 (26%)/679 (74%)
Diabetes
pre-transplant
Yes 265 (28.1%)
Tobacco before
transplant
Yes 319 (34.6%)
Prior cardiovascular
event
Yes 152 (16.5%)
BMI
(at transplantation)
Normal (lower than
25 kg/m2)
503 (54.6%)
Overweight
(25–30 kg/m2)
279 (30.2%)
Obese (greater than
30 kg/m2)
140 (15.2%)
Dialysis duration No dialysis 153 (16.6%)
Dialysis o1 year 277 (30%)
Dialysis 41 year 492 (53.4%)
Modality of dialysis Hemodialysis 491 (53.2%)
Peritoneal dialysis 198 (21.5%)
Both 80 (8.8%)
Prior CMV infection Yes 563 (61.1%)
Beta blocker Yes 174 (18.9%)
Diuretic Yes 83 (9%)
BMI, body mass index; CMV, cytomegalovirus.
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Table 2 | Cardiac events (results of the univariate analysis)
Event-free survival
Variable Categories n Events 1 year 3 years 5 years P-value
Transplant era 1991–1994 444 53 97 95 92 —
1995–1998 478 58 96 93 89 0.037
Age at transplant Younger than 45 495 44 98 96 93 —
45 and older 427 67 95 92 87 0.007
Gender Female 402 39 97 94 92 —
Male 520 72 97 94 89 0.047
Transplant number First 791 96 97 94 90 —
Retransplant 131 15 98 93 90 0.82
Donor type Living 243 16 98 97 94 —
Deceased 679 95 96 93 89 0.017
Prior CMV infection No 354 39 97 95 92 —
Yes 563 72 96 93 89 0.49
Graft function Immediate 704 77 98 95 92 —
Delayed 218 34 93 89 85 0.003
Diabetes pre-transplant No 657 56 98 95 93 —
Yes 265 55 95 90 84 o0.001
Tobacco pre-transplant No 603 43 98 96 94 —
Yes 319 68 95 90 83 o0.001
Prior cardiovascular event No 770 66 98 96 93 —
Yes 152 45 90 84 75 o0.001
Obesity at transplant Normal 503 42 98 97 94 —
Overweight 279 39 95 92 89 —
Obese 140 30 94 90 83 o0.001
Hypertension at transplant No 404 44 97 94 91 —
Yes 518 67 97 93 90 0.28
Hypertension at 3 months No 388 36 99 97 94 —
Yes 433 44 99 95 92 0.67
High cholesterol at transplant No 445 47 97 95 92 —
Yes 456 59 97 94 90 0.38
High cholesterol at 3 months No 177 16 99 97 91 —
Yes 664 70 99 96 93 0.65
Duration of dialysis No dialysis 153 12 98 96 93 —
Less than 1 year 277 22 97 96 95 —
Longer than 1 year 492 77 96 92 87 0.007
Rejection at 3 months None 576 53 99 97 93 —
Single 173 20 99 96 91 —
Multiple 112 16 98 93 90 0.16
Creatinine at 3 months 124 or lower 370 38 98 95 92 —
125–141 223 21 99 98 94 —
142 or higher 264 28 99 96 93 0.74
Pulse pressure at transplant 48 or lower 310 29 98 95 92 —
49–60 305 36 96 93 91 —
61 or higher 307 46 97 93 88 0.036
Pulse pressure at 3 months 45 or lower 245 23 99 96 93 —
46–58 306 26 99 97 94 —
59 or greater 270 31 99 95 91 0.39
Table 2 continued on the following page
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models. The ‘best-fit’ reduced model included diabetes and
peritoneal dialysis, age 445, diabetes, prior CVE, serum
creatinine above 141 mmol/l (1.6 mg/dl) at 3 months (upper
tertile), peritoneal dialysis, and obesity (Table 5). Transplant-
ation after 1994 and overweight status also contributed to the
fit of the model.
Peripheral-vascular events post-transplant were associated
with age 445 (P¼ 0.009), diabetes (Po0.001), tobacco
smoking (P¼ 0.001), previous CVE (Po0.001), peritoneal
dialysis (P¼ 0.012), and male gender (P¼ 0.05). Prior CMV
(P¼ 0.11), DGF (P¼ 0.15), and pulse pressure at 3 months
(P¼ 0.19) were entered in the multivariable models. The only
potential interaction was between prior CMV infection and
tobacco smoking (Figure 1): hazard ratios 1.3 (0.45–2.82), 2
(0.59–4.56), and 6 (2.25–10.01), non-smokerþCMV positive,
smokerþCMV negative, and smokerþCMV positive, re-
spectively. The best-reduced model included diabetes, prior
CMV infection and tobacco smoking, age 445, and prior
CVE. Peritoneal dialysis contributed to the best fit of the
model (Table 5).
Variables associated with mortality were age 445
(Po0.001), deceased donor (Po0.001), DGF (Po0.001),
diabetes (Po0.001), tobacco smoking (Po0.001), prior CVE
(Po0.001), dialysis 41 year (Po0.001), and elevated pulse
pressure at transplantation (P¼ 0.006). Repeated rejections
Table 2 | Continued
Event-free survival
Variable Categories n Events 1 year 3 years 5 years P-value
Type of calcineurin inhibitor Cyclosporine 781 91 97 95 91 —
Tacrolimus 109 12 94 92 89 0.15
Modality of dialysis Hemodialysis 491 70 96 93 89 —
Peritoneal dialysis 198 20 97 95 92 —
Both 80 13 96 93 88 0.29
CMV, cytomegalovirus.
Table 3 | Cardiac events post-transplant (multivariable
analysis, complete model)
Variable Hazard ratioa 95% CI P-value
Prior cardiovascular event 4.59 2.56–8.25 o0.001
Diabetes mellitus 3.94 2.37–6.55 o0.001
Tobacco history 2.89 1.92–4.34 o0.001
Obesity at transplant 2.67 1.60–4.45 o0.001
Multiple rejections 2.05 1.13–3.70 0.02
Dialysis 41 year 1.79 1.15–2.80 0.01
Overweight at transplant 1.54 0.98–2.43 0.06
Single rejection 1.43 0.84–2.42 0.19
Transplant after 1994 1.38 0.89–2.12 0.14
Delayed graft function 1.23 0.78–1.93 0.38
Deceased donor 1.23 0.69–2.18 0.49
Male gender 1.14 0.75–1.72 0.54
Age older than 45 years 1.11 0.72–1.71 0.64
Hypercholesterolemia 1.08 0.73–1.60 0.71
Pulse pressure at transplant 1.05 0.53–1.87 0.9
Immunosuppression (cyclosporine) 0.98 0.47–1.77 0.9
CI, confidence interval.
aHazard ratios adjusted by all the variables listed.
Table 4 | Cardiac events occurring post-transplant
(best-reduced model)
Variable Hazard ratioa 95% CI P-value
Tobacco history 3.53 2.26–5.53 o0.001
Obesity at transplant 2.92 1.69–5.04 o0.001
Diabetes mellitus 2.63 1.70–4.09 o0.001
Multiple rejections 2.19 1.27–3.92 0.008
Prior cardiovascular event 2.00 1.25–3.18 0.004
Dialysis 41 year 1.91 1.20–3.05 0.007
Overweight at transplant 1.68 1.02–2.76 0.04
Age older than 45 years 1.57 0.99–2.38 0.054
Single rejection 1.43 0.85–2.42 0.18
CI, confidence interval.
aHazard ratios adjusted by the other variables listed in the table.
Table 5 | Cerebrovascular, peripheral-vascular events, and
mortality (best-reduced models)
Variable
Hazard
ratioa 95% CI P-value
Cerebrovascular events
Diabetes and peritoneal dialysis 11.95 5.01–28.47 o0.001
Age 445 years 6.77 3.06–14.98 o0.001
Diabetes 4.87 2.07–11.48 o0.001
Prior cardiovascular event 3.73 1.93–7.21 o0.001
Creatinine 4141mmol/l 3.16 1.59–6.30 0.001
Peritoneal dialysis 3.06 1.14–8.26 0.027
Obesity at transplantation 0.32 0.11–0.98 0.046
Overweight at transplant 0.51 0.25–1.04 0.063
Transplant after 1994 0.52 0.26–1.04 0.066
Peripheral-vascular events
Diabetes pre-transplant 8.48 3.97–18.1 o0.001
Tobacco and prior CMV infection 3.88 2.06–7.31 o0.001
Age 445 years 2.31 1.14–4.66 0.019
Prior cardiovascular event 2.25 1.17–4.35 0.016
Peritoneal dialysis 2.13 0.71–6.42 0.18
Mortality
Tobacco and deceased donor 3.52 1.97–6.31 o0.001
Age 445 years 1.81 1.25–2.63 0.002
Diabetes pre-transplant 1.76 1.24–2.51 0.002
Pulse pressure of 61 mm Hg or greater 1.64 1.05–2.55 0.029
Prior cardiovascular event 1.52 1.02–2.26 0.04
Dialysis 41 year 1.47 1.02–2.12 0.04
Hypercholesterolemia at transplant 0.7 0.50–1.00 0.05
CI, confidence interval; CMV, cytomegalovirus.
aHazard ratios adjusted by the other variables listed in the table.
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within the first 3 months (P¼ 0.057), obesity (P¼ 0.09), peri-
toneal dialysis (P¼ 0.1), creatinine at 3 months (P¼ 0.14),
hypertension (P¼ 0.19), gender, and hypercholesterolemia
were also entered in the multivariable models. An interaction
between tobacco smoking and type of organ donor was found
(Figure 2): hazard ratios 1.2 (0.49–2.69), 2.2 (1.26–3.59),
and 4.6 (2.69–7.86), smokerþ live donor, non-smokerþ
deceased-donor, and smokerþdeceased donor, respectively.
The best-reduced model for patient death included history of
tobacco smoking on recipients of a deceased-donor organ,
age 445, diabetes, prior CVE, elevated pulse pressure,
dialysis 41 year, and hypercholesterolemia. Duration of
dialysis was also significant when entered in the model as a
continuous variable (adjusted hazard ratio: 1.07; 95% CI
1.02–1.11; P¼ 0.004).
DISCUSSION
Cardiovascular mortality is increased in patients with chronic
kidney disease.6–8 Mortality from cardiovascular disease is
10–20 times higher among individuals treated with dialysis,
as compared to general population.1 The incidence of
cardiovascular disease in kidney transplant patients is nearly
twice that of the general population.9 Even young transplant
recipients (aged 35–45 years) experienced an almost 10-fold
increase in cardiovascular disease-related mortality.1 Redu-
cing deaths from cardiovascular disease in persons with
chronic kidney disease is one of the Healthy People 2010
objectives.10 Risk factors associated with cardiovascular
disease after transplantation are similar to those described
in population-based studies. However, when traditional
cardiovascular risk scores were applied to a cohort of
transplant recipients, the risks clearly underestimated the
incidence of CVE,2 suggesting that other transplant-specific
factors may contribute to cardiovascular risk either indepen-
dently or by interacting with traditional factors.11 Our study
analyzed the relationships among traditional and transplant-
specific risk factors and cardiovascular outcomes, described
in categories of affected vasculature: cardiac, cerebral, and
peripheral. Fatal and non-fatal events were studied and two-
way interactions among explanatory variables were included
in the analyses.
This report describes associations involving prior CVE
and ischemic events post-transplant in all categories of
vasculature. Until recently,12 prior CVE have not been
accounted for in studies addressing post-transplant CVE.
This factor assumes particular importance as the proportion
of individuals with co-morbid cardiovascular disease at the
time of transplantation has increased from 40% in 1995 to
50% in 2001.13
Interaction terms are used to describe effect-measure
modifications. In other words, an exposure may result in
heterogeneous effects in different strata of subjects. The
importance of analysis of such interactions as a tool to
uncover novel-risk factors is exemplified in our report. It has
been described that recipients of a deceased-donor organ
experience higher incidence of CVE than living-donor
recipients.13 However, we were able to expand such
observation by describing interactions among tobacco and
deceased-donor transplantation in overall mortality, and
between tobacco and CMV infection in the incidence of
peripheral-vascular events. The association between CMV
infection and CVE following transplantation has been
controversial.14–16 Reactivation of latent CMV in endothelial
cells of arteries may contribute to atherogenesis.17 CMV
genetic material and antigens have been detected in
endothelial and deeper layers of diseased human aortas by
in situ hybridization and immunohistochemical staining,18
and in arterial vessels from diabetics undergoing ampu-
tations.19 Antibodies against CMV crossreact with a human
heat-shock protein and cause endothelial cell death in vitro.20
These phenomena may provide the pathophysiologic basis
for the association between CMV infection and arterio-
sclerosis. The role of tobacco smoking in modulating such
disease process should be a target for further research.
Description of an association between renal dysfunction
and cardiovascular disease has been published 15 years ago.21
In the Framingham Heart Study a trend towards an
association between minor renal dysfunction and future
cardiovascular morbidity and mortality was described.6 Data
from the NHANES II have revealed an association between
mild-to-moderate renal insufficiency and increased cardio-
vascular mortality, which was independent from other
traditional risk factors such as diabetes, smoking, or
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Figure 1 | Hazard ratios for post-transplant peripheral-vascular
events. CMV/TOB¼ no prior CMV infection and no history of
tobacco (n¼ 243), þCMV/TOB¼prior CMV infection and no
history of tobacco (n¼ 367), CMV/þ TOB¼ no prior CMV infection
and positive tobacco (n¼ 126), þCMV/þ TOB¼ prior CMV infection
and positive tobacco (n¼ 186).
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Figure 2 | Hazard ratios for death post-transplant. TOB/
LDTx¼ no history of tobacco and living-donor transplant (n¼ 259),
þ TOB/LDTx¼positive tobacco and living-donor transplant (n¼ 64),
TOB/DDTx¼ no history of tobacco and deceased-donor transplant
(n¼ 385), þ TOB/DDTx¼positive tobacco and deceased-donor
transplant (n¼ 214).
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dyslipidemia.22 These findings have been confirmed in
large populations such as the Northern California Kaiser-
Permanente,23 HOT,24 HOPE,25 and VALIANT26 cohorts.
Associations between decreased renal function at 1 year
post-transplantation and hospitalizations owing to acute
coronary syndromes or chronic heart failure4 and mortality5
have been described. We expand these observations by
describing an association between serum creatinine levels
and cerebrovascular events post-transplantation. Associations
between mild renal dysfunction and cerebrovascular events
have been described in a community-based study27 and in a
large interventional trial.26 However, to date, no description
of such association has been reported following renal
transplantation, including in an interventional trial using
fluvastatin following transplantation.28 The association
between loss of allograft function (with return to dialysis)
and CVE has been described previously.29 In our study, 181
patients lost their graft during the observation period.
Survival data were censored at the time of a repeated
transplant (38 patients). Twenty-nine patients are known to
have expired on dialysis. Cardiac events were recorded in nine
of these patients (seven cardio-respiratory arrests and two
myocardial infarcts vs acute coronary syndrome). Censoring
patients at the time of allograft failure did not change our
results significantly.
Associations between obesity at transplantation and
chronic heart failure4 and cardiovascular mortality30 have
been described previously. However, an association between
elevated body mass index and ischemic heart disease has not.
In our study, obesity was associated with cardiac events with
a suggestion of a dose–response phenomenon. The same data
suggest that obesity might have a reverse association with
cerebrovascular events. A competing risks phenomenon
could have played a role in such association (i.e., if a number
of obese individuals would die from other causes soon after
transplantation, a lower proportion would continue to be at
risk for cerebrovascular events later on). However, no
associations between obesity and death either on univariate
or multivariable analyses were found (1 year patient survival
was 98, 95, and 96%, for normal, overweight, and obese,
respectively).
The association between duration of dialysis and cardio-
vascular mortality has been described.4,5,31 In our cohort
study, dialysis longer than 1 year before transplant was
associated not just with mortality but also with non-fatal
cardiac events. A fivefold increased risk for cerebrovascular
events in chronic dialysis patients as compared to the general
population has been described,32 and peritoneal dialysis has
been associated with higher incidence of hospitalizations for
cardiovascular complications, when compared with hemo-
dialysis.4 It has been suggested that peritoneal dialysis is
offered to older patients with a greater number of co-morbid
conditions. This factor could have introduced a selection bias
in our cohort; however, age (44.7711.88 vs 44.1712.03
years; P¼ 0.4) and prevalence of CVE before transplant (17
vs 19.5%; peritoneal vs hemodialysis respectively; P¼ 0.06)
were not different. Furthermore, if a selection bias was
present, we should have observed a higher incidence of
cardiac events or deaths in this group, which was not noted in
our results.
Observational studies are not without limitations. Socio-
economic status has been described as an independent
cardiovascular risk. Unfortunately, our database has incom-
plete data on such variable. Further data on the amount and
duration of tobacco exposure would be needed to establish a
dose–response curve. A larger cohort and longer observation
period would allow for analyses of additional risk factors and
provide enough statistical power to further explore subtle
interactions. A more diverse cohort would allow analysis of
exploratory variables across ethnicities. Our report included
cardio-respiratory arrest as extracted from the death
certificates as part of the primary outcome. Recently, a
different profile of risk factors for either ischemic or non-
ischemic cardiac events has been discussed.33 Unfortunately,
owing to the limited sample size and few potential non-
ischemic events (i.e., sudden deaths), these differences could
not be further evaluated using our cohort. The impact of a
non-fatal event occurring post-transplant on overall mortal-
ity should be explored using a different analytical strategy
such as time-dependent Cox models.
In conclusion, our study has shown that (1) the majority
of CVE were indeed non-fatal, supporting our hypothesis
that mortality data underestimate the burden of cardio-
vascular disease in this population; (2) CVE before transplanta-
tion is a strong factor associated with all categories of CVE
post-transplant (transplant patients carry a burden of pre-
existing cardiovascular disease); (3) interactions among
transplant-specific and traditional risks have a significant
impact on the incidence of CVE post-transplant, suggesting
that a combination of clinical and laboratory variables could
lead to the development of a cardiovascular risk-scoring tools
unique to this population. Furthermore, risk factors such as
duration of dialysis, deceased-donor transplantation, CMV
infection (and prophylaxis), and acute rejection episodes
should be viewed not just as risk factors for allograft failure
but also as cardiovascular risk factors and as targets for
further research and interventions.
MATERIALS AND METHODS
Detailed information on more than 3300 renal transplants at
Oregon Health and Science University has been collected prospec-
tively and entered into a secured database since 1978. The study
cohort includes all adult transplanted between 1 January 1991 and
31 December 1998. This period was chosen to provide a minimal
follow-up of 5 years and a sample size large enough to allow
inclusion of several explanatory variables in the multivariable
models. Patients were followed weekly or bi-weekly for the first 3
months, monthly from months 4 to 6, every 6 months from month
7 to 36 following transplantation, and yearly thereafter. The
standard triple immunosuppressive therapy used during the study
period consisted of a calcineurin inhibitor (either cyclosporine A or
tacrolimus), azathioprine, and prednisone. Since 1999, mycopheno-
late mofetil has been used as a substitute for azathioprine in about
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20% of our cohort, mainly in those with high immunologic risk
(i.e., repeated transplants, high PRA recipients, and those who
experienced delayed onset of graft function or acute rejections
within the first year of transplantation). Beta blockers and diuretics
were used at some point in 18.9 and 9% of recipients, respectively.
Data on angiotensin converting enzyme inhibitors, angiotensin
receptor blockers, and aspirin were not available in the database.
The primary outcome of interest in the study was time to cardiac
event, defined as: length of time between transplantation and the
date of new-onset angina pectoris, acute myocardial infarct,
coronary angioplasty or bypass surgery, or cardiac death (by death
certificate). Acute myocardial infarction was defined according to
the consensus document of The Joint European Society of
Cardiology/American College of Cardiology Committee for the
redefinition of myocardial infarction,34 and other cardiac events
were ascertained by chart reviews of hospital discharge summaries
and procedure records (including angiograms and reports from
percutaneous interventions and surgical revascularizations). Sec-
ondary outcomes were (1) time to cerebrovascular event (time span
from transplantation to first transient ischemic attack, cerebro-
vascular accident, carotid endarterectomy or angioplasty, or death
from a cerebrovascular event), (2) time to peripheral-vascular event:
time to new-onset claudication (confirmed by angiography), limb
revascularization, or amputation, and (3) patient survival. A CVE
was considered fatal if death was recorded within 30 days of a CVE
date. The date of last follow-up was the date of last input in the
database (clinic visit, laboratory data, or death date). Patients were
censored at the date of last follow-up (up to 30 June 2004), if no
events were observed. To ascertain accuracy of mortality data, a
Social Security Administration Death Master File search was
conducted in 30 October 2004 including the entire cohort.
Traditional cardiovascular risks factors analyzed were age,
gender, blood pressure (systolic, diastolic, and pulse pressures),
cholesterol, presence of diabetes, obesity, tobacco smoking, and
history of CVE before transplantation. Transplant-specific risk
factors were time spent on and modality of dialysis before
transplantation, DGF previous CMV infection, type of organ donor
(living or deceased), immunosuppressive regimen, acute rejection
episodes, and serum creatinine at 3 months post-transplant. Body
mass index was calculated by the formula weight (kilograms)/square
of height (meters), and was analyzed both as continuous and as
categorical variables (low to normal: o25 kg/m2; overweight:
25–30 kg/m2; obese: 430 kg/m2). Pulse pressure was calculated by
subtracting the diastolic from the systolic blood pressures and also
analyzed as continuous and categorical variables (tertiles). Hyper-
tension was defined by a systolic 4140 mm Hg, a diastolic 490 mm
Hg, or the use of antihypertensive drugs. Hypercholesterolemia was
defined by fasting total cholesterol 45.2 mmol/l (4200 mg/dl) or
by the use of lipid-lowering drugs. Categories of modality of dialysis
were none, hemodialysis, peritoneal dialysis, or both. DGF was
defined by dialysis within the first week post-transplant. Immuno-
suppression was categorized by the type of calcineurin inhibitor
(cyclosporine or tacrolimus). Continuous variables were entered as
such in the models or were transformed into categories either by
using tertiles (pulse pressure and creatinine levels) or by using cutoff
levels based on previous publications (age, body mass index, and
time on dialysis). The decision to describe a variable either as
continuous or categorical was based on the best fit of the
multivariable models. With the exception of death, other CVE were
not mutually exclusive. Event-free survival curves were constructed
using the product-limit method (Kaplan–Meier). Differences among
survival curves were estimated by the log rank test. Cox proportional
hazards models were built using variables with a P-value lower than
0.2 in the univariate analyses, and variables considered to be of
biological significance (age, gender, hypertension, hypercholestero-
lemia, previous CVE, tobacco smoking, and diabetes). Direct
visualization of log(log (survival time)) vs log (survival time)
plots was used to validate the proportionality of hazard increments
assumption. Results were reported as hazard ratios with correspon-
dent 95% CI and P-values. Pre-established two-way interactions
between each of the transplant-specific variables and traditional risk
factors were screened and, if significant, entered into the multi-
variable models. The significance of a cluster of independent
variables was analyzed by using the likelihood-ratio test. Single
variables were removed from the complete models and the ratios of
the likelihoods of the reduced models to the complete models were
calculated on a stepwise fashion. Best-fit reduced models were found
once no further variables could be removed. P-values lower than
0.05 (two tailed) were considered significant. SPSS 11.5 for windows
(SPSSs Inc., Chicago, IL, USA) was used in the analysis. The
protocol was approved by the local institution review board.
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